Abstract
Acute leukemia (AL), which includes acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL), is a hematological malignancy characterized by the uncontrolled proliferation of immature myeloid or lymphoid cells. Allogeneic stem cell transplantation (ASCT) remains a therapeutic option for patients with AL. Determination of transplantation indications is a key step in successful ASCT and in curing patients. Currently, the measurable residual disease (MRD) is used as a biomarker for response evaluation, relapse prediction, preemptive therapy, and post-remission treatment selection. In this review, we discuss the advantages and disadvantages of these techniques for MRD detection. We focused mainly on the residual disease-directed selection of transplant indications for patients with either AML or ALL and provided expert opinions in these settings. We also discuss the challenges associated with transplantation indications and propose expert opinions and future directions for the selection of indications for transplantation.